Capsulotomy for OCD

Capsulotomy is a lesioning procedure (creating a small, permanent, precisely placed change in brain tissue, rather than implanting a device) used as an alternative to deep brain stimulation for a small number of patients with severe, treatment-resistant OCD. The target is a specific part of the anterior limb of the internal capsule, a region involved in the same circuits that DBS targets for OCD, described on our OCD page. Stereotactic capsulotomy has been refined and used for several decades and remains an established, if less commonly used, option in appropriately selected patients, alongside DBS.

A precisely placed lesion is created at the target using stereotactic planning based on the patient’s imaging. This can be done using stereotactic radiofrequency lesioning (a heated probe), MR-guided focused ultrasound (an incisionless technique, similar in concept to the MRgFUS used for tremor, described on our Movement Disorders pages), or Gamma Knife radiosurgery (a non-invasive, radiation-based stereotactic technique performed without any incision, with the effect on tissue developing gradually over weeks to months rather than immediately). Which technique is used depends on the equipment available and the specific clinical situation and is discussed individually.

Both treatments target related circuits and are considered for the same group of patients: those with severe, treatment-resistant OCD, following the same multidisciplinary evaluation process described on our OCD page. The key difference is reversibility. DBS is adjustable and can be turned off or removed; capsulotomy creates a permanent lesion that cannot be adjusted or reversed once made. Capsulotomy avoids the ongoing presence of implanted hardware, programming visits and battery replacement, which is why it is sometimes considered when long-term device follow-up would be impractical, or when a patient prefers not to have an implanted device; but this permanence also means the decision to proceed is made with particular care.

Candidacy follows the same criteria as DBS for OCD: severe, disabling OCD that has not responded to genuine, appropriately delivered trials of medication and exposure and response prevention therapy, confirmed through independent psychiatric assessment and multidisciplinary case review involving psychiatry, neurosurgery and neuropsychology.

Evaluation is the same thorough, multidisciplinary process described on the OCD page; confirmation of diagnosis and treatment history, structured symptom rating, neuropsychological assessment, and joint case review before any decision is made.

The realistic goal is a meaningful reduction in the severity of obsessions and compulsions and improved day-to-day function, in appropriately selected patients; not a cure and not guaranteed for any individual. As with DBS for OCD, benefit typically develops gradually, and ongoing psychiatric care continues after the procedure.

Because the lesion created is permanent, any effect that occurs, wanted or unwanted, cannot be reversed by adjusting a device, unlike DBS. Recognized risks include changes in personality, motivation or behavior (such as apathy or reduced initiative), which are taken particularly seriously given the frontal location of the target, along with the general risks of a stereotactic procedure, including bleeding, infection (for techniques involving an incision), and seizure. Response is not guaranteed, and, as with DBS, unrealistic expectations should be avoided from the outset.

Recovery depends on the technique used: incisionless approaches (MRgFUS etc.) generally involve a shorter hospital stay than techniques requiring an incision. Ongoing psychiatric care and follow-up continue after the procedure in all cases, in the same way as after DBS.